anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The Agatsuma et al's study shows that despite the evidence of the benefits of an early colorectal cancer (CRC) diagnosis, through screening in asymptomatic subjects, up to 50% of candidates reject this option and many of those affected are diagnosed later, in advanced stages. The efficacy of screening programs has been well-established for several years, which reduces the risk of CRC morbidity and mortality, without taking into account the test used for screening, or other tools. Nevertheless, a significant proportion of patients remain unscreened, so understanding the factors involved, as well as the barriers of the population to adherence is the first step to possibly modify the participation rate. These barriers could include a full range of social and political aspects, especially the type of financial provision of each health service. In Japan, health services are universal, and this advantageous situation makes it easier for citizens to access to these services, contributing to the detection of various diseases, including CRC. Interestingly, the symptomatic CRC group had a lower early-stage diagnosis rate than the patients detected during follow-up for other comorbidities, and symptomatic and cancer screening groups showed similar early-stage diagnosis.
PURPOSE: A manufacturing method of polymer microspheres is provided to manufacture the polymer microspheres with an excellent monodispersion property by minimizing the use of sample through the simple method. CONSTITUTION: A manufacturing method of a microsphere by using a polymer monomer and a solvent which is not be mixed with the polymer monomer comprises the following steps. A step of preparing a reproduced mold in which a microwell which satisfies the condition in which a height/maximum width is less than 1.0 and a minimum width/maximum width to the same direction is less than 0.4 is formed. A step of filling a polymer monomer in the microwell of the reproduced mold. A step of applying a solvent which has lower density than the polymer monomer and which has a higher wettability to the reproduced mold than the polymer monomer. A step of polymerizing the polymer monomer.
Participants will consume a tart cherry or placebo product for 30 days and attend 5 visits in the Exercise Physiology Lab at Ohio University over the 30 day period. They will self-collect a stool sample at baseline, 14 days and 30 days after supplementation. Blood samples will be taken at baseline, 7 days, 14 days, and 30 days after supplementation. Throughout the study participates will rate symptoms (stomach, head, etc.), pain and sleep quality using an online survey for which the link will be emailed. Participants will maintain normal diet and exercise routine and to track these for the duration of the study.
PROBLEM TO BE SOLVED: To obtain a food for infants useful especially for the infants requiring the control on the ratio of an n-6 series/n-3 series polyvalent unsaturated fatty acids in order to especially develop a brain or nervous systems or patients suffering from allergic diseases by regulating the ratio with a perilla oil and blending the resultant edible oil and fat therein. SOLUTION: This food for infants is prepared by regulating the n-6 series/n-3 series unsaturated fatty acid ratio to 0.1-7, preferably 0.3-6 with a perilla oil at 0.3 fatty acid ratio described above and blending the resultant edible oil and fat therein. Concretely, a modified milk is obtained by preparing, e.g. an oil and fat at 6 fatty acid ratio mentioned above, replacing an oil and fat used in a well-known modified milk converted into a breast milk with the resultant oil and fat. Thereby, an excellent modified milk further converted into a breast milk is obtained. Furthermore, a food and a drink for preventing the allergy or a food and a drink for patients suffering from allergic diseases are preferably prepared by regulating the fatty acid ratio to about 4 without using an animal oil and fat as the oil and fat.  In addition, the use of soybean oil, rice oil, corn oil, etc., is preferably restrained by considering the grain allergy.
OBJECTIVES: Hyperglycaemia-induced inflammation plays a vital role in the development of diabetic peripheral neuropathy (DPN). Recent evidences had reported the involvement of the transcription factor nuclear factor kappa-light-chain-enhancer of activated B cell (NF-κB) in diabetic experimental models. So, this pilot study aimed to evaluate serum NF-κB levels in DPN patients.
METHODS: We recruited 50 T2DM patients, of which 25 were T2DM with neuropathy and 25 were T2DM without neuropathy. In all the participants peripheral neuropathy was diagnosed based on Total neuropathy score (TNS). Serum NF-κB levels were measured by ELISA.
RESULTS: We observed that the serum NF-κB levels were higher in DPN patients in comparison to T2DM patients without neuropathy. On spearman correlation, a positive correlation was found between serum NF-κB levels and TNS in the DPN group (r=0.741, p<0.001). The regression model shows the TNS to be an independent determinant of serum NF-κB levels after adjustment for potential confounders like age, duration of diabetes, and HbA1C (B=81.34; p<0.001).
CONCLUSIONS: NF-κB activation plays a key role in promoting inflammation which is associated with the progression of DPN. In this respect, the study of NF-κB levels in serum may be an additional diagnostic marker for DPN.
Perform 2 sets of 6-10 breaths through a POWERbreathe device, which applies a variable resistance provided by an electronically controlled valve (variable flow resistive load). The training device will be set at 30% of the highest value of three MIP maneuvers. A two-minute rest period with MV support will be provided between each set.
Productivity loss because of chronic pain in the working age population is a widespread concern internationally. Interventions for chronic pain in working age adults might be expected to achieve enhanced productivity in terms of reduced costs of workers' compensation insurance, reduced disability support, and improved rates of return to work for injured workers. This would require the use of measures of productivity in the evaluation of chronic pain management interventions. The aim of this review was to identify and interpret the productivity outcomes of randomised controlled trials reported by studies that conducted economic evaluations (eg, cost-effectiveness and cost-utility) of chronic pain management interventions in the working age population published from database inception to March 2023. Econlit, Embase, and Pubmed electronic databases were searched, yielding 12 studies that met the selection criteria. All 12 studies used absenteeism to measure productivity, translating return to work measures into indirect costs. Only one study included return to work as a primary outcome. Ten studies found no statistically significant improvements in productivity-related costs. Despite evidence for reduced pain-related disability after pain management interventions, this review suggests that the use of measures for assessing productivity gains is lacking. Including such measures would greatly assist administrators and payers when considering the broader societal benefits of such interventions.
This was a hospital-based prospective observational study performed at a tertiary academic center from September 2020 to August 2021.

Patients diagnosed with acute mild biliary pancreatitis according to the Revised Atlanta classification 2012 were enrolled from the Emergency/Outpatient Department. Detailed history taking and thorough general and systemic examinations were conducted. Eligible patients were informed about treatment options (early vs. delayed LC) and provided informed written consent. Randomization into "early" or "delayed" groups was performed, and detailed investigations were conducted. To avoid bias, randomization was accomplished by lottery method. In the early group, laparoscopic cholecystectomy was performed during the same admission, while delayed group patients underwent surgery after symptom resolution and readmission. Surgeries were performed under general anesthesia with standard laparoscopic techniques with surgeons of equivalent qualifications. Postoperative care included analgesics and antibiotics, with follow-up examinations and histopathological assessments conducted at specified intervals. Oral intake and pain management protocols were implemented postoperatively, with patients monitored for recovery and instructed to return to normal activities after staple removal. Patients were asked to complete a visual analog pain score (VAS) from 0 (no pain) to 10 (intolerable pain) on the seventh postoperative day.
Participants received 600 mg Linezolid twice daily I.V. infusion to oral for 10 days.
Psoriasis is a multifactorial, chronic, and inflammatory disease that severely impacts patients' quality of life. The disease is caused by genetic irregularities affected by epigenetic and environmental factors. Some of these factors may include seasonal changes, such as solar radiation, air pollution, and humidity, and changes in circadian rhythm, especially in the temporal and polar zones. Thus, some psoriasis patients report seasonal variability of symptoms. Through a comprehensive review, we aim to delve deeper into the intricate interplay between seasonality, environmental factors, and the genetic and epigenetic landscape of psoriasis. By elucidating these complex relationships, we strive to provide insights that may inform targeted interventions and personalized management strategies for individuals living with psoriasis.
Single ascending doses of ONO-2808 or placebo orally under fasted conditions. Additional descriptive information (including which interventions are administered in each arm) to differentiate each arm from other arms in the clinical trial.
In the event of an overdose with JENTADUETO, contact the Poison Control Center. Employ the usual supportive measures (e.g., remove unabsorbed material from the gastrointestinal tract, employ clinical monitoring, and institute supportive treatment) as dictated by the patient’s clinical status. Removal of linagliptin by hemodialysis or peritoneal dialysis is unlikely. However, metformin is dialyzable with a clearance of up to 170 mL/min under good hemodynamic conditions. Therefore, hemodialysis may be useful partly for removal of accumulated metformin from patients in whom JENTADUETO overdosage is suspected.

Linagliptin

During controlled clinical trials in healthy subjects, with single doses of up to 600 mg of linagliptin (equivalent to 120 times the recommended daily dose), there were no dose-related clinical adverse drug reactions. There is no experience with doses above 600 mg in humans.

Metformin

Overdose of metformin has occurred, including ingestion of amounts greater than 50 grams. Hypoglycemia was reported in approximately 10% of cases, but no causal association with metformin has been established. Lactic acidosis has been reported in approximately 32% of metformin overdose cases [see Boxed Warning and Warnings and Precautions (5.1)].
The current standard of care (SoC) for SARS-CoV-2 testing for Fortune clients is referral to offsite community testing sites and informal, unstructured education. In the SoC arm, Fortune staff will provide clients with a list of offsite SARS-CoV-2 testing locations, which are published online and available to all NYC residents. Those without insurance are not subject to a copay. Participants in SoC will continue to receive Fortune's suite of services as they are delivered (remote and/or in-person) at the time of study participation.
A head mounted displaying system and an image generating method thereof are provided. The head mounted displaying system includes a displaying device, a movement sensor, a frame, an image generating system and a physiological information sensor. The movement sensor senses a movement of an object or senses a movement of the displaying device. The frame is configured to fix the displaying device. The image generating system is coupled to the displaying device. The image generating system displays an image through the displaying device. The image includes a first part. The first part is irrelative to a sensing result of the movement sensor. The physiological information sensor is disposed at the frame and coupled to the image generating system. The image generating system adjusts the first part of the image displayed by the displaying device according to physiological information sensed by the physiological information sensor.
For the first week of the 8 week treatment period, patients received valsartan 160 mg, placebo to valsartan, and 2 tablets of placebo to aliskiren. For the remaining 7 weeks of the study, patients received valsartan 320 mg (two 160 mg capsules) and 2 tablets of placebo to aliskiren. The tablets and capsules (2 of each) were taken orally once daily each morning. To evaluate a missed dose, the last dose of medication was administered at the clinic, and the patient was scheduled to return 2 days later for exercise testing (8 weeks + 2 days).
Aqueous solution of ranitidine free of ethanol. The present invention relates to an aqueous solution of ranitidine free of ethanol and to the use thereof for the preparation of a medicament for the prevention and/or treatment of duodenal and gastric ulcer, prevention and/or treatment of gastrointestinal hemorrhages. and the treatment of peptic esophagitis. The solution is particularly appropriate for administration to patients under 3 years of age. Said solution comprises a taste masking system based on sucrose and/or sorbitol, and a combination of a buffering system with a preservative which gives it a high stability despite having a high concentration of active principle. (Machine-translation by Google Translate, not legally binding)
In the ST period, participants were administered a dose of 125 mg abatacept SC, once weekly, for 4 months. Participants were also administered a stable MTX dose of greater than or equal to 10 mg once weekly for at least 4 weeks prior to first injection of SC abatacept.
Aflatoxin is a naturally occurring mycotoxin that has numerous toxic effects. The main aim of the present study was to evaluate the toxic effects of aflatoxin B1 (AFB1) on the lungs and spleen. Mice were repeatedly exposed to AFB1 (0.3 mg/kg body weight) on alternate days for four weeks via oral route. The histopathological data in AFB1-treated mice show alveolar epithelial hyperplasia with inflammation and the presence of numerous alveolar macrophages with minimal hemorrhage. There was an increase in vascular neutrophils and interstitial inflammation. The branching of vessels was plugged with neutrophils. AFB1 administration also causes splenomegaly. The AFB1-treated spleen shows the tingible body macrophages (TBM) scattered within the splenic white pulp. Apoptosis may lead to atrophy in a selected region of the white pulp area. There is a decrease in cellularity within the periarteriolar lymphatic sheath (PALS). The inflammation causes the congestion of red pulp with the increase in nuclear debris, and vacuoles are also visible. The flow cytometry data further suggests enhanced apoptosis in lung and spleen cells.
The present invention represents the first systems biology approach to investigate the volunteers' immune predisposition to respond to a vaccination (proteins trimer GP160 SOSIP), assessed by their blood transcriptome profile; specifically, that related to their B cell differentiation stages. That is, inventors investigated the host gene expression in blood by a microarray approach before vaccination. The objective was to examine their potential involvement in an effective SOSIP neutralizing antibody (Nabs) response during a randomized phase lb clinical study. This trial immunized 6 HIV seronegative subjects by the intramuscular route with SOSIP -HIV clade B vaccine. Inventors found that gene expression of a group of genes (detected through mRNA nucleic acids in blood) are overexpressed at baseline in subjects with the highest antibody response compared to the subjects with the lowest antibody response, and therefore may be considered as good biomarkers to assess the humoral immune response of a subject to a vaccine. Accordingly, the present invention relates to methods and kits for predicting the humoral response of a subject prior to vaccination. More specifically present invention relates to methods for assessing the humoral response of a subject to a vaccine through detection in a blood sample of specific RNAs.
We will collect two repeated spot urine samples, a DBS sample and obtain weight in all 600 study participants. In a randomly selected subsample (n=200) a third repeat spot urine sample and one 24 h urine will additionally be collected.
Anthropometric measurements of the hand were measured with a digital caliper. Anthropometric measurements were determined as hand length, width and finger lengths, taking into account previous studies. Manual dexterity was evaluated with the 9-Hole Peg Test.
* Take levetiracetam exactly as prescribed. Levetiracetam is usually taken twice a day. Once in the morning and once at night.Take levetiracetam at the same times each day.
  * Your healthcare provider may start you on a lower dose of levetiracetam and increase it as your body gets used to the medicine.
  * Take levetiracetam with or without food. Swallow the tablets whole. Do not chew or crush tablets. Use the levetiracetam oral solution if you cannot swallow tablets. Use a medicine dropper or medicine cup to measure levetiracetam oral solution. Do not use a teaspoon. Ask your pharmacist for a medicine dropper or medicine cup to help you measure levetiracetam. If your healthcare provider has given you levetiracetam oral solution for your child, be sure to ask your pharmacist for a medicine syringe to help you measure the correct amount of levetiracetam oral solution. Ask your pharmacist for instructions on how to properly use the medicine syringe or dosing device that has been provided to you.
  * If you miss a dose of levetiracetam, do not double your next dose to make up for the missed dose. If it has only been a few hours since your missed dose, take levetiracetam as soon as you remember then return to your regular schedule. If it is almost time for the next dose, skip the missed dose and resume your regular schedule. Talk with your healthcare provider for more detailed instructions.
  * If you take too much levetiracetam or overdose, call your local Poison Control Center or emergency room right away.
  * Do not stop taking levetiracetam or any other seizure medicine unless your healthcare provider told you to. Stopping a seizure medicine all at once can cause seizures that will not stop (status epilepticus), a very serious problem.
  * Tell your healthcare provider if your seizures get worse or if you have any new types of seizures.
Midazolam is widely used for intravenous sedation. However, wide interindividual variability is seen in the sensitivity to midazolam. The association between genetic factors and interindividual differences in midazolam sensitivity remains unclear. The present study explored the association between common genetic variants and sedative and amnesic effects of midazolam. This prospective study included patients who were scheduled to undergo dental procedures under intravenous sedation. The sedative effect was evaluated using the Ramsay sedation scale 5 min after midazolam (0.05 mg/kg) administration. We employed two parallel approaches in this study: genome-wide approach and candidate gene approach. The γ-aminobutyric acid type A receptor subunit genes were selected as candidate genes. Multivariate linear regression analyses were performed to investigate the association between the Ramsay sedation scale and genetic variants. We also analyzed the association between the presence of anterograde amnesia and genetic variants using multivariate binominal logistic regression analyses. The analyses were adjusted for potential confounding factors. A total of 191 patients were included in the analyses. In the genome-wide association analyses, no significant association was found between the genetic variants and Ramsay scores. In the candidate gene analyses, the rs73247636 (dominant model: β = 0.72 [95% confidence interval, 0.34 to 1.10], P < 0.001) and rs56278524 (dominant model: β = 0.73 [0.37 to 1.10], P < 0.001) polymorphisms of the GABRB1 gene were significantly associated with Ramsay scores. Additionally, the rs73247636 (dominant model: odds ratio [OR] = 8.39 [2.36 to 29.85], P = 0.001) and rs56278524 (dominant model: OR = 15.26 [3.42 to 68.07], P < 0.001) polymorphisms were also significantly associated with the presence of anterograde amnesia. The rs73247636 and rs56278524 single-nucleotide polymorphisms of GABRB1 were associated with the sedative and amnesic effects of midazolam.
Despite its clinical value, cascade genetic testing (CGT) in hereditary cancer syndromes remains underutilized for a number of reasons, including ineffective family communication of genetic risk information. Therefore, alternative strategies are being explored to improve CGT uptake rates; one such strategy is direct contact with at-risk relatives by healthcare professionals with proband consent. It is unclear how Italian laws and regulations pertaining to CGT-including the EU General Data Protection Regulation (GDPR)-should be understood and implemented in the context of such alternative strategies. The authors constructed a hypothetical case about CGT, reviewed laws and regulations on informed consent, privacy, and the right not to know, and analyzed how those laws and regulations might apply to different communicative strategies relevant to the case and aimed at supporting CGT. A constitutionally consistent reading of Italian law and of the GDPR, an integral part of the Italian privacy framework, suggests that multiple communicative approaches may be legally permissible in Italy to support the CGT process. This includes direct contact by healthcare professionals with proband consent, provided certain conditions are met. Understanding the effectiveness of such approaches in improving CGT uptake will require further research efforts.
The present invention relates to a medicine for treating osteoporosis and a production method thereof. The medicine is prepared from psoralea fruit, desertliving cistanche, astragalus root, epimedium herb, dodder seed and red sage root as main raw materials which are jointly made into oral formulations, such as oral medicinal liquids, oral medicinal powder, medicinal granules, tablets or capsules, etc. The medicine of the present invention has the effects of invigorating the kidney, strengthening the bones, promoting blood circulation to remove meridian obstruction, fortifying the spleen and boosting qi. The medicine mainly treats osteoporosis, can relieve symptoms, can increase bone mass, can improve the biodynamic performance of the bones, and enables the bone mass to be recovered to different degrees. The present invention has the advantages of rapid effect taking, convenient administration, obvious increase of the bone mass, small side effect, etc. The production method is simple.
This arm includes the Family Food \& Lifestyle intervention (FL). Parents and children meet for 12 weekly, 90-minute psychoeducational groups in children's schools. They meet separately for 45 minutes and then conjointly for 45 minutes.
Azacitidine will be given intravenously for 7 days. Venetoclax will be given orally. The patient will start out with 100mg and progress to 600mg. Once 600mg is reached, the patient will stay at this dose until the 28 day cycle is finished.
In the control group, fluid management was set as MAP (Mean arterial pressure) 65 mmHg and above and diuresis 0.5ml/kg/hour and above. Crystalloid infusion at 7ml/kg/hour was started. When SVV value increased to 13% and over in the study group, 250 ml of crystalloid was given in the first stage, and if it continued to be 13% and over, 250 ml of colloid bolus was given. Vasoconstrictor agent was used when SVV was below 13% and MAP was below 65 mmHg.